Mesa Laboratories: approves restructuring, $2,600,000 to $3,400,000

What happened

• The filing says the board approved a restructuring program on Oct 6, 2026 and the company began notifying affected employees on Oct 12, 2026.
• The program "announced" the elimination of approximately 40 positions, primarily in the Clinical Genomics division, additional reductions in corporate functions, and the exit of the Hamburg, Germany facility when its lease expires in Feb 2027.

Key details

• The company estimates total pre-tax charges of approximately $2,600,000 to $3,400,000, primarily during the second half of fiscal year 2027.
• Estimated charges consist of employee-related costs of approximately $2,300,000 to $3,000,000 (net of an expected non-cash reversal of approximately $300,000 of previously recognized stock-based compensation) and other exit costs of approximately $300,000 to $400,000.
• Expected related cash expenditures are approximately $2,900,000 to $3,700,000, substantially all of which the filing says will occur over the next 12 months.
• The filing says the Restructuring Program is expected to be substantially complete by the end of fiscal year 2027, except for certain international employee exits subject to protected notice periods expected to complete in the first half of fiscal year 2028.

Why it may matter

• The filing reports Item 2.05 (costs associated with exit or disposal activities), which covers the estimated charges and cash expenditures tied to the announced restructuring program.
• The filing notes these are preliminary estimates and that actual charges and timing may differ. This filing does not show why the company acted.